Efavirenz drug data and news

---

Balloon can put a heart in order  07 Mar 2006
...be treated. I have no doubt that Mr Martin has been given a diet and prescribed an anti-cholesterol tablet like simvastatin. Most ... - Scotsman,

Keep your cholesterol in check with Simvastatin  Feb 9, 2006
...levels. The most prominent cholesterol drugs belong to the statin family, including Simvastatin and Atorvastatin to name a few. ... - LiveArticles.org,

Anti-cholesterol drug combo okay for muscles  Feb 22, 2006
NEW YORK (Reuters Health) - Ezetimibe plus simvastatin, a combination of two anti-cholesterol drugs marketed by Merck/Schering-Plough Pharmaceuticals as Vytorin ... - Reuters

How can I prevent my children from becoming travel sick?  Mar 2, 2006
...from Romford in which the reader is so attached to grapefruit for breakfast that he is not certain that he wouldn’t rather give up simvastatin (Zocor and ... - Times Online,

Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts ...  Feb 23, 2006
In addition, during 2005 Kos announced the commencement of the AIM-HIGH morbidity/mortality study with Niaspan/simvastatin, jointly sponsored with National ... - Genetic Engineering News,

Romania: Sicomed Takeover Raises Zentiva's Turnover  Mar 1, 2006
...product promoting teams.". Simvastatin is the market leader in its respective sector, according to company estimates. Zentiva intends ... - Reporter.gr,

Health Alert: Statin Power  Feb 14, 2006
Letcher. He's in a study to see if a statin drug, Simvastatin, sold as Zocor, can boost his brain power and slow the disease. Dr ... - WIS,

Cholesterol drug OK opens cash artery for Genepharm  Feb 1, 2006
By Rebecca Urban. GENERIC drug maker Genepharm will be able to sell its own version of lucrative cholesterol treatment Simvastatin from April. ... - The Age,

1 From the Harvard Medical School and Brigham and Women's Hospital ...  Feb 17, 2006
Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. ... - Am J Clin Nutr (subscription),

Nutrition: Red Grapefruit Earns a Star on Cholesterol Test  Feb 20, 2006
The researchers tested 57 patients ages 39 to 72 who had undergone coronary bypass surgery and had found that Zocor, or simvastatin, was ineffective. ... - New York Times,

Red grapefruit earns a star on cholesterol test  Feb 22, 2006
The researchers tested 57 patients ages 39 to 72 who had undergone coronary bypass surgery and had found that Zocor, or simvastatin, was ineffective. ... - International Herald Tribune,

Prescription at a cost  Feb 20, 2006
The two top-selling statins - atorvastatin sold as Lipitor and simvastatin sold as Lipex and Zocor - cost the Government more than $770 million in the past ... - Australian,

Statins To Reduce Cholesterol Levels  Feb 24, 2006
...for use in the US: Lipitor® (atorvastatin), Lescol® (fluvastatin), Mevacor® (lovastatin), Pravachol® (pravastatin), Zocor® (simvastatin) and Crestor ... - WSOCtv.com,

Dr Reddy`s to sell 2 Merck generics  Feb 1, 2006
...s Laboratories has signed an agreement with Merck & Co of the US to sell and distribute generic versions of two of its drugs, Zocor (simvastatin) and Proscar ... - Business Standard,

Cutting Certain Pills in Half Can Help Reduce Costs  Feb 19, 2006
...experiment by the US Department of Veterans Affairs health system in which eligible patients split tablets of the cholesterol-lowering drug simvastatin in half ... - International News Service,

Case 4-2006 — A 79-Year-Old Woman with Myalgias, Fatigue, and ...  Feb 9, 2006
Hyperlipidemia had been diagnosed six years earlier and had been controlled with simvastatin. Three years before admission, treatment ... - New England Journal of Medicine (subscription),

Stock Watch  Feb 23, 2006
The organisation has signed an agreement with Merck to sell and distribute generic versions of two of its drugs, Zocor (simvastatin) and Proscar (finasteride ... - Express Pharma Pulse,

Study: Red grapefruit helps heart  Feb 21, 2006
The researchers tested 57 patients, ages 39 to 72, who had undergone coronary bypass surgery and had found that Zocor, or simvastatin, was ineffective. ... - Los Angeles Daily News,

Biotech on high  Feb 1, 2006
The Melbourne company told the Australian Stock Exchange the drug, known as simvastatin, had reached the final stage before sales begin. ... - Melbourne Herald Sun,

Drug sales boost shares 13pc  Feb 1, 2006
Genepharm directors told the stock exchange the drug - known as simvastatin - had reached the final stage before sales begin. Simvastatin ... - Daily Telegraph,

Pfizer Driving Performance Through Growth of Current and New ...  Feb 10, 2006
...benefits. In addition, Lipitor is performing well against generic simvastatin in many markets where the two medicines compete. This ... - MSN Money

Cholesterol drug move  Feb 1, 2006
Genepharm Australia has reached the final stage of approval from the Therapeutic Goods Administration to sell its version of the drug simvastatin, the company ... - Advertiser Adelaide,

Splitting pills slices costs  Feb 13, 2006
Veterans Affairs said it saved $46.5 million in 2003 by having eligible patients split pills for the cholesterol-lowering drug simvastatin, commercially sold ... - Poughkeepsie Journal,

Roche to Focus Resources on Availability of Invirase, Now ...  Feb 6, 2006
...saquinavir in this population. Concomitant use of Invirase with lovastatin or simvastatin is not recommended. Caution should be ... - DG News

Volunteers needed for drug study  Feb 17, 2006
Additional volunteers are being sought for a study into possible interaction between vitamin E and the cholesterol-reducing drugs simvastatin (often marketed ... - Corvallis Gazette Times,

Medicine return haul a huge waste  Feb 14, 2006
Lipex, also known as simvastatin, has joined the top four medicines most often wasted, along with the stomach acidity regulator losec, 300mg aspirin and the ... - Manawatu Standard,

Research and Markets: Pfizer's Atorvastatin + Torcetrapib ...  Feb 17, 2006
...combination is expected to have a major impact on the dyslipidemia market and is expected to compete with both atorvastatin and Vytorin (simvastatin + ezetimibe ... - Genetic Engineering News,

Pill-splitting plan could be a big cost saver  Feb 5, 2006
The department of Veteran s Affairs saved $46.5 million in 2003 by encouraging eligible patients who took simvastatin, commercially sold as Zocor, to split ... - Portsmouth Herald News,

Medical Spending To Treat Hyperlipidemia Up 350% 1996-2003, USA  Feb 14, 2006
Total expenditures for Lipitor (Atorvastatin), the top-selling drug, were 7.8 billion, while expenditures for Zocor (Simvastatin) totaled 5.5 billion. ... - Medical News Today (press release),

Strong demand for statin drugs pushes up sales  Feb 14, 2006
Known as “statin drugs� or “statins,� Lipitor (atorvastatin) and Zocor (simvastatin) work by blocking the liver enzyme responsible for the production ... - Wilkes Barre Times-Leader,

Do Lackluster Trial Findings Mean New Avenues Are Needed for Heart ...  Feb 9, 2006
...in reducing the risk of major coronary events among patients with previous myocardial infarction, compared with usual-dose (20 mg/d) simvastatin (Pedersen TR ... - Journal of American Medical Association (subscription),

Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ...  Feb 9, 2006
Taking APTIVUS/r with rifampin, St. John's wort, lovastatin, or simvastatin is not recommended. This list of medications is not complete. ... - PR Newswire (press release),

Toprol XL uncertainty weighs heavy on AstraZeneca  Feb 3, 2006
...although it remains to be seen whether it will be able to maintain this growth rate once generic versions of Merck & Co's Zocor (simvastatin) and Bristol-Myers ... - Pharma Times (subscription),

Merck profits edge ahead in fourth quarter  Feb 1, 2006
...helped by a 12% hike in revenues from asthma drug Singulair (montelukast) to $819 million, as well as a contribution from Vytorin (simvastatin and ezetimibe). ... - Pharma Times (subscription),

Pfizer's updated 2006 forecast disappoints  Feb 13, 2006
...drug, the cholesterol-lowerer Lipitor (atorvastatin), are likely to be dented by competition in the form of Merck & Co's rival Zocor (simvastatin), which is ... - Pharma Times (subscription),

The Market for Metabolic Syndrome Therapies is Forecast to ...  Feb 1, 2006
Some of the most widely prescribed drugs for constituents of the metabolic syndrome (eg, metformin, glibenclamide, simvastatin, lovastatin, pravastatin ... - International News Service,

Pharmac Agrees To Fund Vytorin Cholestrol Drug  Feb 1, 2006
Merck Sharp and Dohme, says one part of the drug, ezetimibe, inhibits absoprtion of cholesterol, while the more common statin, simvastatin, lowers cholesterol. ... - newswire.co.nz,

Efavirenz has been shown in vivo to induce CYP3A4. Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz). In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations. Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug. Therefore, appropriate dose adjustments may be necessary for these drugs.

Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations. Drug interactions with SUSTIVA are summarized in Table 5.

Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.

Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine. Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.